Prellis Biologics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 60

Employees

  • Latest Deal Type
  • Series C1

  • Investors
  • 15

Prellis Biologics General Information

Description

Developer of a bioprinting technology designed to recreate and engineer human tissues in vitro. The company's technology precisely reproduces the human immune response through the creation of lymph node organoids and can exploit fully human immune responses for a variety of applications, including antibody discovery, immunogenicity assessment, and tumor-immune models, improving patients' lives by addressing challenges commonly faced in early-stage drug discovery and translational pharmacology.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 999 Anthony Street
  • Berkeley, CA 94710
  • United States
+1 (415)
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 999 Anthony Street
  • Berkeley, CA 94710
  • United States
+1 (415)

Prellis Biologics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Prellis Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series C1) 27-May-2026 Completed Generating Revenue
8. Later Stage VC (Series C) 28-Nov-2023 Completed Generating Revenue
7. Later Stage VC (Series C) 10-Aug-2022 Completed Generating Revenue
6. Later Stage VC (Series B) 14-Jul-2021 Completed Generating Revenue
5. Secondary Transaction - Private 03-May-2021 Completed Generating Revenue
4. Early Stage VC (Series A) 21-Mar-2019 Completed Startup
3. Seed Round 19-Apr-2018 Completed Startup
2. Accelerator/Incubator 22-Jun-2017 $250K $250K Completed Startup
1. Accelerator/Incubator Completed Startup
To view Prellis Biologics’s complete valuation and funding history, request access »

Prellis Biologics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B Prime
Series B
Series A
Seed Prime 1,191,043 $0.000100 8% $0.21 $0.21 1x $0.21 0.87%
Seed 6,634,718 $0.000100 8% $0.27 $0.27 1x $0.27 4.84%
To view Prellis Biologics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Prellis Biologics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a bioprinting technology designed to recreate and engineer human tissues in vitro. The company's technology
Other Healthcare Technology Systems
Berkeley, CA
60 As of 2026

Vancouver, Canada
 

Tampa, FL
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Prellis Biologics Competitors (13)

One of Prellis Biologics’s 13 competitors is Aspect Biosystems, a Venture Capital-Backed company based in Vancouver, Canada.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aspect Biosystems Venture Capital-Backed Vancouver, Canada
TransGenex Nanobiotech Formerly Accelerator/Incubator backed Tampa, FL
PrintBio Venture Capital-Backed Long Island City, NY
Frontier Bio Venture Capital-Backed Hayward, CA
InSphero Private Equity-Backed Schlieren, Switzerland
You’re viewing 5 of 13 competitors. Get the full list »

Prellis Biologics Patents

Prellis Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026035990-A2 Methods of generating antibodies that are human from the start Pending 09-Aug-2024
WO-2026035990-A3 Methods of generating antibodies that are human from the start Pending 09-Aug-2024
US-20250353252-A1 Methods and systems for three-dimensional printing Pending 01-Jun-2022
WO-2023114785-A2 Three-dimensional bio-engineered lymphoid organs and organoids for cell-based therapies Inactive 14-Dec-2021
WO-2023114785-A3 Three-dimensional bio-engineered lymphoid organs and organoids for cell-based therapies Inactive 14-Dec-2021 B33Y80/00
To view Prellis Biologics’s complete patent history, request access »

Prellis Biologics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Prellis Biologics Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
Open Field Capital Venture Capital Minority
Avidity Partners Asset Manager Minority
Black Diamond Ventures Venture Capital Minority
Celesta Capital Venture Capital Minority
Future Ventures (San Francisco) Venture Capital Minority
You’re viewing 5 of 15 investors. Get the full list »

Prellis Biologics FAQs

  • When was Prellis Biologics founded?

    Prellis Biologics was founded in 2016.

  • Where is Prellis Biologics headquartered?

    Prellis Biologics is headquartered in Berkeley, CA.

  • What is the size of Prellis Biologics?

    Prellis Biologics has 60 total employees.

  • What industry is Prellis Biologics in?

    Prellis Biologics’s primary industry is Other Healthcare Technology Systems.

  • Is Prellis Biologics a private or public company?

    Prellis Biologics is a Private company.

  • What is Prellis Biologics’s current revenue?

    The current revenue for Prellis Biologics is .

  • How much funding has Prellis Biologics raised over time?

    Prellis Biologics has raised $70.2M.

  • Who are Prellis Biologics’s investors?

    Open Field Capital, Avidity Partners, Black Diamond Ventures, Celesta Capital, and Future Ventures (San Francisco) are 5 of 15 investors who have invested in Prellis Biologics.

  • Who are Prellis Biologics’s competitors?

    Aspect Biosystems, TransGenex Nanobiotech, PrintBio, Frontier Bio, and InSphero are some of the 13 competitors of Prellis Biologics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process